Literature DB >> 16740106

Comparative pharmacokinetics of meloxicam in clinically normal horses and donkeys.

Melissa D Sinclair1, Katrina L Mealey, Nora S Matthews, Ken E Peck, Tex S Taylor, Brad S Bennett.   

Abstract

OBJECTIVE: To determine the disposition of a bolus of meloxicam (administered IV) in horses and donkeys (Equus asinus) and compare the relative pharmacokinetic variables between the species. ANIMALS: 5 clinically normal horses and 5 clinically normal donkeys. PROCEDURES: Blood samples were collected before and after IV administration of a bolus of meloxicam (0.6 mg/kg). Serum meloxicam concentrations were determined in triplicate via high-performance liquid chromatography. The serum concentration-time curve for each horse and donkey was analyzed separately to estimate standard noncompartmental pharmacokinetic variables.
RESULTS: In horses and donkeys, mean +/- SD area under the curve was 18.8 +/- 7.31 microg/mL/h and 4.6 +/- 2.55 microg/mL/h, respectively; mean residence time (MRT) was 9.6 +/- 9.24 hours and 0.6 +/- 0.36 hours, respectively. Total body clearance (CL(T)) was 34.7 +/- 9.21 mL/kg/h in horses and 187.9 +/- 147.26 mL/kg/h in donkeys. Volume of distribution at steady state (VD(SS)) was 270 +/- 160.5 mL/kg in horses and 93.2 +/- 33.74 mL/kg in donkeys. All values, except VD(SS), were significantly different between donkeys and horses. CONCLUSIONS AND CLINICAL RELEVANCE: The small VD(SS) of meloxicam in horses and donkeys (attributed to high protein binding) was similar to values determined for other nonsteroidal anti-inflammatory drugs. Compared with other species, horses had a much shorter MRT and greater CL(T) for meloxicam, indicating a rapid elimination of the drug from plasma; the even shorter MRT and greater CL(T) of meloxicam in donkeys, compared with horses, may make the use of the drug in this species impractical.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16740106     DOI: 10.2460/ajvr.67.6.1082

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  7 in total

1.  Pharmacokinetics of 3 formulations of meloxicam in cynomolgus macaques (Macaca fascicularis).

Authors:  Cassondra Bauer; Patrice Frost; Stephen Kirschner
Journal:  J Am Assoc Lab Anim Sci       Date:  2014-09       Impact factor: 1.232

2.  Pharmacokinetics and bioequivalence of 2 meloxicam oral dosage formulations in healthy adult horses.

Authors:  Melanie Vivancos; Jessica Barker; Sarah Engbers; Carrie Fischer; Jami Frederick; Heather Friedt; Joanna M Rybicka; Tereza Stastny; Heidi Banse; Alastair E Cribb
Journal:  Can Vet J       Date:  2015-07       Impact factor: 1.008

3.  Aqueous stability and oral pharmacokinetics of meloxicam and carprofen in male C57BL/6 mice.

Authors:  Joelle C Ingrao; Ron Johnson; Elizabeth Tor; Yu Gu; Marcus Litman; Patricia V Turner
Journal:  J Am Assoc Lab Anim Sci       Date:  2013-09       Impact factor: 1.232

4.  Pharmacokinetics of meloxicam after oral administration of a granule formulation to healthy horses.

Authors:  Francisco Javier Mendoza; Juan Manuel Serrano-Rodriguez; Alejandro Perez-Ecija
Journal:  J Vet Intern Med       Date:  2019-02-15       Impact factor: 3.333

5.  Molecular characterization of Gyps africanus (African white-backed vulture) organic anion transporter 1 and 2 expressed in the kidney.

Authors:  Bono Nethathe; Rephima Phaswane; Aron Abera; Vinny Naidoo
Journal:  PLoS One       Date:  2021-05-04       Impact factor: 3.240

6.  Pharmacokinetics of butorphanol following intravenous and intramuscular administration in donkeys: A preliminary study.

Authors:  Lisa Ebner; Odette O; Bradley Simon; Ignacio Lizarraga; Joe Smith; Sherry Cox
Journal:  Front Vet Sci       Date:  2022-09-23

7.  Meloxicam ameliorates the systemic inflammatory response syndrome associated with experimentally induced endotoxemia in adult donkeys.

Authors:  Francisco Javier Mendoza Garcia; Carlos Gonzalez-De Cara; Raul Aguilera-Aguilera; Antonio Buzon-Cuevas; Alejandro Perez-Ecija
Journal:  J Vet Intern Med       Date:  2020-05-28       Impact factor: 3.333

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.